CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope

Vamika Karn, Sandhya Sandhya, Wayne Hsu, Deepak Parashar, Himanshu Narayan Singh, Niraj Kumar Jha, Saurabh Gupta, Navneet Kumar Dubey, Sanjay Kumar

Research output: Contribution to journalReview articlepeer-review

20 Citations (Scopus)


Cancer is one of the major causes of mortality worldwide, therefore it is considered a major health concern. Breast cancer is the most frequent type of cancer which affects women on a global scale. Various current treatment strategies have been implicated for breast cancer therapy that includes surgical removal, radiation therapy, hormonal therapy, chemotherapy, and targeted biological therapy. However, constant effort is being made to introduce novel therapies with minimal toxicity. Gene therapy is one of the promising tools, to rectify defective genes and cure various cancers. In recent years, a novel genome engineering technology, namely the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9) has emerged as a gene-editing tool and transformed genome-editing techniques in a wide range of biological domains including human cancer research and gene therapy. This could be attributed to its versatile characteristics such as high specificity, precision, time-saving and cost-effective methodologies with minimal risk. In the present review, we highlight the role of CRISPR/Cas9 as a targeted therapy to tackle drug resistance, improve immunotherapy for breast cancer.

Original languageEnglish
Article number234
JournalCancer Cell International
Issue number1
Publication statusPublished - Dec 2022


  • Breast cancer
  • CRISPR/Cas9
  • Diagnosis
  • Drug resistance
  • Gene editing
  • Immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research


Dive into the research topics of 'CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope'. Together they form a unique fingerprint.

Cite this